Original ArticlesThe efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease☆,☆☆
Section snippets
Patients
Twenty-one patients (12 males and 9 females), ranging in age from 8 months to 35 years, with neuronopathic Gaucher’s disease were evaluated (Table I).At the time of enrollment, 3 patients were adults (age range, 18-30 years) and 18 were children (age range, 8 months-15 years). Seven patients underwent partial or complete splenectomy before enrollment, and one patient had a partial splenectomy during the follow-up period. Four patients were receiving ERT when they entered the study. The length
Enzyme Doses
The enzyme doses ranged between 120 IU/kg and 480 IU/kg of body weight/4 wk; 18 patients received biweekly doses of 60 IU/kg. Patient 3 responded only to 120 IU/kg/2 wk; patient 9 received 60 IU to 120 IU/kg/wk in an attempt to induce tolerance to the enzyme after development of neutralizing antibodies.32 Initially, patient 11 did not respond to an enzyme dose of 120 IU/kg/wk but did respond after a partial splenectomy (see below). Currently, all but 3 patients receive 60 IU/kg every 2 weeks.
Discussion
ERT is safe and effective in reversing most of the systemic manifestations of chronic neuronopathic (type 3) Gaucher’s disease in a large cohort of patients. The treatment rapidly reduced organomegaly and corrected hematologic abnormalities. ERT improved femoral cortical bone thickness and normalized the bone marrow signal on T1-weighted MRI images. Although cortical bone thickness was determined only in the femur and does not necessarily reflect other skeletal regions, this finding documented
Acknowledgements
We thank the patients and their families for their participation, Dr Thierry Billette de Villemeur for referral of patients, and Devera G. Schoenberg, MS, for editorial assistance.
References (37)
- et al.
Gaucher’s disease: clinical features and natural history
- et al.
Liver abnormalities in patients with Gaucher’s disease
Gastroenterology
(1981) - et al.
Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease
Lancet
(1998) - et al.
Enzyme replacement therapy in type 1 and type 3 Gaucher’s disease
Lancet
(1994) - et al.
Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease
Clin Biochem
(2000) - et al.
Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase
J Pediatr
(1996) - et al.
Enzyme replacement therapy in type 1 and type 3 Gaucher’s disease
Lancet
(1995) - et al.
Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
Lancet
(2000) - et al.
Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease
J Clin Invest
(1966) - et al.
Gaucher disease
Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s disease
Ann Neurol
Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease
Neurology
Neuronopathic forms of Gaucher disease
Gaucher’s disease complicated by bleeding esophageal varices and colonic infiltration by Gaucher cells
Am J Gastroenterol
Gaucher’s disease and portal hypertension
Br J Surg
Pulmonary hypertension and Gaucher’s disease: logical association or mere coincidence?
Am J Pediatr Hematol Oncol
Gaucher disease type I (adult type), with massive involvement of the kidneys and lungs
Virchows Arch
Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher’s disease
N Engl J Med
Cited by (148)
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders
2022, Advanced Drug Delivery ReviewsCitation Excerpt :Although ERT is effective in reversing hepatosplenomegaly and hematologic manifestations, limitations were identified from these early studies, including insufficient reversal of pathologies in organs such as muscle, bone, cartilage, heart and lungs. Unfortunately, ERTs offer marginal benefits in cases where there are neurological complications – this may result from the inability of replacement enzymes to cross the blood–brain barrier (BBB) [38–40]. Moreover, host antibodies recognize infused (recombinant) enzyme molecules and result in their rapid removal from serum.
Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience
2021, European Journal of Medical GeneticsTargeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease
2021, Acta Pharmaceutica Sinica BCitation Excerpt :Therefore, the enhancement of GCase activity may be also applied in the treatment of PD. However, since GCase cannot transverse the blood−brain barrier, the direct application of enzyme replacement therapy is ineffective for PD155. Later, it was proposed to develop small-molecule drug chaperones which could be used as an alternative therapy for PD156,157.
Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma
2021, Molecular Genetics and MetabolismAllogeneic hematopoietic stem cell transplantation for treating severe lung involvement in Gaucher disease
2020, Molecular Genetics and Metabolism ReportsEEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review
2020, Molecular Genetics and Metabolism
- ☆
*Collaborators: Tappas K. Bannarjee, MD, K. Crutchfield, MD, Karen Frei, MD, Mary-Ann McKee, MD, David F. Moore, MD, PhD, DIC, and Ann Tournay, MD
- ☆☆
Reprint requests: Raphael Schiffmann, MD, National Institutes of Health, Building 10, Room 3D03, 9000 Rockville Pike, Bethesda, MD 20892-1260.